Clinical assessment, platelet reactivity measurement or genetic testing after acute coronary syndrome? What benefits the patient?

EuroIntervention. 2013 Jul;9(3):299-301. doi: 10.4244/EIJV9I3A50.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acute Coronary Syndrome / therapy*
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Drug Resistance / genetics*
  • Drug-Eluting Stents*
  • Female
  • Humans
  • Male
  • Percutaneous Coronary Intervention / instrumentation*
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Polymorphism, Single Nucleotide*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine